Clinical trial
A Phase I Dose Escalation Study of Oral MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT00670488 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation Study of Oral MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 15, 2008
- Completion date
- July 11, 2011
- Enrollment
- 104 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, locally advanced tumors, metastatic solid tumors, neoplasms